---
title: A Study to Compare 2 Formulations of LY900014 in Healthy Participants
nct_id: NCT03334448
overall_status: COMPLETED
phase: PHASE1
sponsor: Eli Lilly and Company
study_type: INTERVENTIONAL
primary_condition: Healthy
countries: Singapore
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03334448.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03334448"
ct_last_update_post_date: 2020-05-01
last_seen_at: "2026-05-12T07:32:20.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study to Compare 2 Formulations of LY900014 in Healthy Participants

**Official Title:** Bioequivalence Study Comparing the Pharmacokinetics and Glucodynamics of LY900014 U-200 Formulation With LY900014 U-100 Formulation in Healthy Subjects

**NCT ID:** [NCT03334448](https://clinicaltrials.gov/study/NCT03334448)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 49
- **Lead Sponsor:** Eli Lilly and Company
- **Conditions:** Healthy
- **Start Date:** 2017-12-04
- **Completion Date:** 2018-03-15
- **CT.gov Last Update:** 2020-05-01

## Brief Summary

The study involves a comparison of a LY900014 U-200 formulation with a LY900014 U-100 formulation. LY900014 is a type of fast acting insulin. Study participants will be administered LY900014 U-100 two times and LY900014 U-200 two times, over 4 study periods, by injection under the skin. Blood samples will be taken to compare how the body handles the study drugs and how they affect the blood sugar levels. Side effects and tolerability will be documented. The study will last about 4 weeks, not including screening and follow up. Screening is required within 28 days prior to the start of the study and follow up is required at least 2 weeks after the last dose of study drug.

## Eligibility

- **Minimum age:** 21 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy male or a female (not pregnant and agreeable to take birth control measures until study completion)
* Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²)
* Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study
* Have veins suitable for easy blood collection and glucose solution infusion

Exclusion Criteria:

* Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
* Have previously participated or withdrawn from this study
* Had blood loss of more than 450 milliliters (mL) within the last 3 months
* Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female)
* Smoke more than 10 cigarettes per day
* Are infected with hepatitis B or human immunodeficiency virus (HIV)
* Are taking illegal drugs
```

## Arms

- **LY900014-U200** (EXPERIMENTAL) — Single subcutaneous (SC) dose of 15 units (U) LY900014 U-200 in two of four study periods
- **LY900014-U100** (EXPERIMENTAL) — Single SC dose of 15 U LY900014 U-100 in two of four study periods

## Interventions

- **LY900014-U200** (DRUG) — Administered SC
- **LY900014-U100** (DRUG) — Administered SC

## Primary Outcomes

- **Pharmacokinetics (PK): Insulin Lispro Area Under Plasma Concentration Curve Zero to 10 Hours (AUC[0-10])** _(time frame: Predose, 5 minutes (mn), 10mn, 15mn, 20mn, 25mn, 30mn, 35mn, 40mn, 45 mn, 50mn, 55 mn, 60mn, 70mn,90mn,120mn,150mn,180mn, 240mn,300mn,360mn,320mn, 480mn, 540mn, and 600mn (10 hours))_ — Insulin Lispro AUC From Time Zero to 10 hours post dose (AUC\[0-10h\])

## Secondary Outcomes

- **Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm** _(time frame: Predose, every minute from run-in and for the duration of the EC until up to 10 hours postdose)_

## Locations (1)

- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore

## Recent Field Changes (last 30 days)

- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri, 9 am to 5 pm eastern time (utc/gmt - 5 hours, est) or speak with your personal physician.|singapore||singapore` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03334448.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03334448*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*